After the national conference on deploying visits to listed companies and promoting the high-quality development of listed companies was held, the Shanghai Stock Exchange took action as soon as possible. It is understood that as of February 6, the special working group of the Shanghai Stock Exchange has visited and investigated nearly 50 companies on the Science and Technology Innovation Board, listened to the specific difficulties and demands faced by listed companies in their high-quality development, actively took measures to coordinate and solve the problems of enterprise development, and increased support for high-quality listed companies.
Among them, a number of biopharmaceutical-related listed companies said that they are full of confidence in the prospects for the high-quality development of the domestic biopharmaceutical industry, and will actively respond to changes in the internal and external environment of the industry, promote the company's growth with high-level research and development, high-quality products, and efficient management, continue to practice the development concept of "investor-oriented" listed companies, and safeguard the rights and interests of investors for a long time.
The biomedical industry is a national strategic emerging industry with high-precision and cutting-edge technologies, which is related to people's livelihood and well-being, and is also one of the core areas supported by the Science and Technology Innovation Board. At present, there are a total of 111 listed biomedical companies on the Science and Technology Innovation Board, with outstanding industrial agglomeration, forming a number of innovative enterprises with small molecule chemical drugs, monoclonal antibodies, vaccines, biological products, in vitro diagnostic reagents, medical equipment and consumables as the main development direction.
Domestic innovative products set sail to the sea
Biomedical companies on the STAR Market are the "vanguard" of China's innovative pharmaceutical and medical device enterprises, and the "new force" of China's R&D to participate in global competition. The core products of the Science and Technology Innovation Board, represented by BeiGene and InnoCare, have been approved for listing in the European and American markets to achieve "independent going overseas" or "borrowing ships to go overseas" through the authorization of international pharmaceutical companies, which has enhanced the international competitiveness of China's biopharmaceutical industry. In recent years, innovative products have set sail to the sea, forming an agglomeration effect among companies on the Science and Technology Innovation Board.
According to Junshi Biosciences, one of the company's core products, toripalimab, was approved in 2023 to become the first and only drug for nasopharyngeal carcinoma in the United States, which is also the first innovative biologic drug independently developed and produced in China approved by the U.S. Food and Drug Administration (FDA). The company continues to expand its global commercialization network, and has reached commercialization cooperation with partners in Latin America, India, South Africa, Southeast Asia, Australia, New Zealand and other countries and regions for toripalimab.
According to Xinmai Medical, the company currently has 13 products on the market, mainly covering thoracic aortic and abdominal aortic stent grafts, intraoperative stents, drug balloon dilatation catheters, peripheral vascular stents, balloon dilatation catheters and other products, which have entered more than 30 countries and regions overseas, saving the lives of more than 230,000 patients around the world. According to the company's 2023 annual performance forecast, the company's operating income in 2023 will increase by more than 30% year-on-year, of which overseas sales will increase by more than 50% year-on-year, and the proportion of the company's total revenue will be further increased. The company will also further promote the overseas registration and approval of key innovative products, and continuously improve the global strategic layout.
In recent years, the innovative achievements of the companies on the STAR Market have been gradually recognized by international pharmaceutical companies. In December 2023, Baili Tianheng reached an exclusive license and cooperation agreement with Bristol-Myers Squibb, a global biopharmaceutical company, on its self-developed BL-B01D1 innovative drug, with a potential total transaction value of up to US$8.4 billion, setting a record for the down payment of domestic innovative drug licensing transactions, and also setting a new record for the total price of global ADC single drug transactions, and is the first bispecific antibody ADC new drug to successfully go overseas.
Innovative pharmaceutical and medical device products have been approved for marketing one after another
The innovative products of biomedical companies on the Science and Technology Innovation Board have been approved for listing one after another, and the R&D results have been continuously realized, and the profit foundation has been continuously consolidated.
According to minimally invasive electrophysiology, the company is committed to providing a globally competitive "integrated solution for diagnosis and ablation with precise interventional navigation as the core". In 2023, the company's cryoablation products, pressure catheters, and a new generation of Columbus 3D electrophysiological mapping system have been approved at home and abroad, promoting the domestic substitution process of atrial fibrillation. The company's electrophysiology centralized procurement products won the bid, and the globalization strategy continued to advance, with the cumulative number of surgeries exceeding 50,000 cases, and the market share and brand influence continued to rise.
According to Xuantai Pharmaceutical, the company will actively promote the research and development, registration and commercialization of new products in the second half of 2023, with a total of 7 products approved at home and abroad, 3 products included in medical insurance, and 2 products won the bid for national centralized procurement. With the continuous expansion of the company's commercial varieties, the company's net profit increased by 41% quarter-on-quarter in the third quarter of 2023.
According to Yifang Biopharma, the two indications of the Class 1 innovative drug befatinib mesylate capsule jointly developed by the company and Betta Pharmaceuticals were approved by the State Food and Drug Administration in May and October 2023, respectively, and included in the National Medical Insurance Catalogue in December 2023. Befacitinib is a third-generation EGFR-TKI that is expected to generate R&D and sales milestone payments for the company.
Mabwell introduced that since its listing on the Science and Technology Innovation Board, the company has promoted the approval of two products, such as adalimumab and denosumab, which are mainly oriented to the field of autoimmune diseases, with a large market space, and have been fully launched for commercial sales. The company has another 2 varieties that are expected to be approved for marketing in 2024.
Actively enhance investors' sense of gain
Improving the quality of listed companies and enhancing investor returns is the proper meaning of the development of listed companies. A number of biopharmaceutical companies on the Science and Technology Innovation Board stated that they will continue to focus on their main business, strengthen R&D and innovation, continuously improve their operating performance, and implement "improving quality and efficiency and emphasizing returns"; At the same time, the company will earnestly fulfill the responsibilities and obligations of listed companies, establish a good market image, and help boost market confidence, stabilize the capital market and develop the economy with high quality.
Long Xiaohui, chairman of Nanwei Medical, said: "The company will continue to practice the action of 'improving quality and efficiency and emphasizing returns', do a good job in the company's main business, create good products for people's lives and health, and at the same time standardize corporate governance, earnestly fulfill the responsibilities of listed companies, actively repay the trust of investors, and jointly ensure the smooth operation of the science and technology innovation board market." ”
Baike Biotech said that the company always pays attention to the embodiment of the company's value in the capital market, attaches great importance to the operation and development of the enterprise, and enhances the value of the enterprise and returns the majority of shareholders with good performance.
The reporter paid attention to the recent upsurge of "improving quality, efficiency and return" actions of the science and technology innovation board companies, practicing the "investor-oriented" development concept with practical measures and maintaining the stability of the company's stock price and jointly promoting the stable operation of the market. Since the beginning of the year, more than 130 companies on the STAR Market have issued a new round of repurchase and increase plans, with a total amount of more than 10 billion yuan. Among the biopharmaceutical companies, United Imaging Medical, a leading domestic imaging equipment company, disclosed a repurchase plan of 400 million yuan to 800 million yuan in the early stage, and MGI, a leader in gene sequencing, 2A repurchase plan of 500 million yuan to 500 million yuan is also being implemented.
Zhang Xiaolin, chairman and CEO of Dizhe Pharmaceutical, and two senior executives in key positions jointly plan to increase their holdings of the company's shares to a maximum of 13 million yuan. Zhang Xiaolin said: "The company will earnestly fulfill the responsibilities and obligations of listed companies, repay the trust of investors, maintain the company's market image, and jointly promote the smooth operation of the science and technology innovation board market." ”